
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 3, Issue 1 11-16, Copyright © 1997 by American Association for Cancer Research
ARTICLES |
AK Bednarek, A Sahin, AJ Brenner, DA Johnston and CM Aldaz
Department of Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas 78957, USA.
Telomerase activity has been implicated to be associated with most human malignant tumors, including breast cancer. To evaluate possible associations with well-known prognostic factors in breast cancer, we performed a semi-quantitative analysis of telomerase activity levels using the very sensitive PCR-mediated telomeric repeat amplification protocol. Telomerase activity was detected in 99 of 104 breast cancer samples analyzed (95.2%), whereas no activity was detected in 10 of 10 adjacent nonmalignant breast tissues. Analysis of five breast fibroadenoma samples revealed telomerase activity in one (20%). In contrast to previous observations, we observed that 100% of stage I breast tumors were positive for telomerase activity. More interestingly, we detected telomerase activity in six of six ductal carcinoma in situ samples (i.e., stage 0). In our semiquantitative analysis of levels of enzymatic activity, we found no statistically significant correlation at the P < h 0.05 level between telomerase levels and lymph node metastasis status, estrogen and progesterone receptor status, tumor size, S-phase fraction, and ploidy. The only statistically significant correlation was found with patient age (rho = -0.3; P = 0.03). We observed no statistically significant difference in the telomerase activity levels of early tumors (stages 0 and 1) versus more advanced lesions (stages II to IV). Nevertheless, stage IV tumors displayed a tendency for higher telomerase activity levels. In summary, no clear association was observed between telomerase levels and known breast cancer prognostic indicators. However, telomerase detection by the telomeric repeat amplification protocol method, due to its high sensitivity, may be of value in early breast cancer diagnosis and detection, because our data indicate that telomerase reactivation appears to constitute a relatively early event in breast carcinogenesis.
This article has been cited by other articles:
![]() |
K.-D. Wu, L. M. Orme, J. Shaughnessy Jr, J. Jacobson, B. Barlogie, and M. A. S. Moore Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival Blood, June 15, 2003; 101(12): 4982 - 4989. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-S. Herbert, A. C. Wright, C. M. Passons, W. E. Wright, I. U. Ali, L. Kopelovich, and J. W. Shay Effects of Chemopreventive and Antitelomerase Agents on the Spontaneous Immortalization of Breast Epithelial Cells J Natl Cancer Inst, January 3, 2001; 93(1): 39 - 45. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Meyerson Role of Telomerase in Normal and Cancer Cells J. Clin. Oncol., July 1, 2000; 18(13): 2626 - 2634. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Bièche, C. Noguès, V. Paradis, M. Olivi, P. Bedossa, R. Lidereau, and M. Vidaud Quantitation of hTERT Gene Expression in Sporadic Breast Tumors with a Real-Time Reverse Transcription-Polymerase Chain Reaction Assay Clin. Cancer Res., February 1, 2000; 6(2): 452 - 459. [Abstract] [Full Text] |
||||
![]() |
L. A. Carey, N. W. Kim, S. Goodman, J. Marks, G. Henderson, C. B. Umbricht, J. S. Dome, W. Dooley, S. R. Amshey, and S. Sukumar Telomerase Activity and Prognosis in Primary Breast Cancers J. Clin. Oncol., October 1, 1999; 17(10): 3075 - 3081. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Dome, S. Chung, T. Bergemann, C. B. Umbricht, M. Saji, L. A. Carey, P. E. Grundy, E. J. Perlman, N. E. Breslow, and S. Sukumar High Telomerase Reverse Transcriptase (hTERT) Messenger RNA Level Correlates with Tumor Recurrence in Patients with Favorable Histology Wilms' Tumor Cancer Res., September 1, 1999; 59(17): 4301 - 4307. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Poremba, K. R. Shroyer, M. Frost, R. Diallo, F. Fogt, K.-L. Schafer, H. Burger, A. L. Shroyer, B. Dockhorn-Dworniczak, and W. Boecker Telomerase Is a Highly Sensitive and Specific Molecular Marker in Fine-Needle Aspirates of Breast Lesions J. Clin. Oncol., July 1, 1999; 17(7): 2020 - 2020. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bednarek, A. Shilkaitis, A. Green, R. Lubet, G. Kelloff, K. Christov, and C. M. Aldaz Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumors Carcinogenesis, May 1, 1999; 20(5): 879 - 883. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |